Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHARMAPATCH is a transdermal ketamine delivery system being developed by PharmaTher Holdings Ltd. for the management of acute postoperative and chronic pain. The patch utilizes proprietary microneedle technology to provide controlled, sustained release of ketamine, an NMDA receptor antagonist, aiming to maintain constant therapeutic plasma levels for over 24 hours while minimizing side effects associated with peak-and-trough concentrations. Developed via the FDA 505(b)(2) regulatory pathway, PHARMAPATCH is designed as a non-opioid alternative for analgesia and includes anti-tampering and anti-abuse features. Beyond pain management, the company is exploring its potential in mental health indications such as treatment-resistant depression, suicidality, and PTSD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PHARMAPATCH.